DUBLIN--(BUSINESS WIRE)--Dublin - Research and Markets (http://www.researchandmarkets.com/research/9f29208e/diabetic_foot_ulce) has announced the addition of Global Markets Direct's new report "Diabetic Foot Ulcers - Pipeline Review, H1 2012" to their offering.
Global Markets Direct's, 'Diabetic Foot Ulcers - Pipeline Review, H1 2012', provides an overview of the Diabetic Foot Ulcers therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Foot Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers. 'Diabetic Foot Ulcers - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Key Topics Covered:
- Introduction
- Global Markets Direct Report Coverage
- Diabetic Foot Ulcers Overview
- Therapeutics Development
- An Overview of Pipeline Products for Diabetic Foot Ulcers
- Diabetic Foot Ulcers Therapeutics under Development by Companies
- Diabetic Foot Ulcers Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Diabetic Foot Ulcers Therapeutics - Products under Development by Companies
- Diabetic Foot Ulcers Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Diabetic Foot Ulcers Therapeutics Development
- Diabetic Foot Ulcers - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Diabetic Foot Ulcers Therapeutics - Drug Profile Updates
- Diabetic Foot Ulcers Therapeutics - Discontinued Products
- Diabetic Foot Ulcers Therapeutics - Dormant Products
- Diabetic Foot Ulcers - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
Companies Mentioned:
- Cardium Therapeutics, Inc.
- Sanofi-Aventis
- Biotec Pharmacon ASA
- CardioVascular BioTherapeutics, Inc.
- Reliance Life Sciences Pvt. Ltd.
- Nanotherapeutics, Inc.
- Pfizer Inc.
- RegeneRx Biopharmaceuticals, Inc.
- Pluristem Therapeutics Inc.
- Microbio Co., Ltd.
- CytoTools AG
- Healthpoint, Ltd.
- Glycotex, Inc.
- Phage Biotechnology Corporation
- NovaLead Pharma Pvt. Ltd.
- BRIDGE BIORESEARCH PLC
- USV Limited.
- CoDa Therapeutics, Inc.
- Innocoll, Inc.
- Adocia
- Agennix AG
- Praxis Pharmaceuticals Inc.
For more information visit http://www.researchandmarkets.com/research/9f29208e/diabetic_foot_ulce
Source: Global Markets Direct